Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Current Liabilities: 2015-2025

Historic Total Current Liabilities for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $22.4 million.

  • Seres Therapeutics' Total Current Liabilities fell 65.40% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year decrease of 65.40%. This contributed to the annual value of $41.2 million for FY2024, which is 58.22% down from last year.
  • As of Q3 2025, Seres Therapeutics' Total Current Liabilities stood at $22.4 million, which was down 27.51% from $30.9 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Total Current Liabilities registered a high of $108.3 million during Q2 2024, and its lowest value of $22.4 million during Q3 2025.
  • In the last 3 years, Seres Therapeutics' Total Current Liabilities had a median value of $64.8 million in 2024 and averaged $65.2 million.
  • Per our database at Business Quant, Seres Therapeutics' Total Current Liabilities skyrocketed by 106.67% in 2021 and then plummeted by 71.43% in 2025.
  • Seres Therapeutics' Total Current Liabilities (Quarterly) stood at $82.3 million in 2021, then rose by 4.06% to $85.6 million in 2022, then rose by 15.26% to $98.7 million in 2023, then slumped by 58.22% to $41.2 million in 2024, then plummeted by 65.40% to $22.4 million in 2025.
  • Its Total Current Liabilities was $22.4 million in Q3 2025, compared to $30.9 million in Q2 2025 and $31.3 million in Q1 2025.